-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 11, Xianju Pharmaceutical announced that it had recently received the "Approval Notice for Supplementary Drug Application" for Flumazenil Injection approved and issued by the State Food and Drug Administration.
Flumazenil is a selective gamma-aminobutyric acid type A receptor (GABAA) antagonist, which recognizes BDZ receptor drugs by competitively inhibiting the gamma-aminobutyric acid-benzodiazepine complex (GABA-BDZ), and then It reduces the release of γ-aminobutyric acid (GABA) and reverses the central inhibitory effect of GABA release.